Alumis is a biotechnology company focused on developing treatments for autoimmune disease, and their goal is to create therapies that are more precise than currently available autoimmune or immune-mediated disease treatments. Alumis was founded in 2021 and is headquartered in San Francisco, CA. Through its data analytics platform, Alumis seeks to enable researchers to match the right patients to targets, molecules, and combinations so they can create the best possible outcomes.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/06/2024 | Series C-1 | $4.00 | $xx.xx | $702.67MM | Ally Bridge Group, Ayurmaya, Cormorant Asset Management, Foresite Capital, Hbm Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare, Samsara Biocapital, Sr One, Venbio Partners | |
Price per Share
$xx.xx
Shares Outstanding
1
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Ayurmaya, Cormorant Asset Management, Foresite Capital, Hbm Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare, Samsara Biocapital, Sr One, Venbio Partners
|
||||||
03/06/2024 | Series C | $259MM | $xx.xx | $702.67MM | Ally Bridge Group, Ayurmaya Capital Management, Cormorant Asset Management, Foresite Capital, Hbm Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare, Samsara Biocapital, Sr One, Venbio Partners | |
Price per Share
$xx.xx
Shares Outstanding
82,529,809
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Ayurmaya Capital Management, Cormorant Asset Management, Foresite Capital, Hbm Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare, Samsara Biocapital, Sr One, Venbio Partners
|
||||||
05/08/2023 | Series B-2 | $90MM | $xx.xx | $607.01MM | Ayurmaya Capital Management, Foresite Capital | |
Price per Share
$xx.xx
Shares Outstanding
18,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ayurmaya Capital Management, Foresite Capital
|
||||||
05/08/2023 | Series B-2A | $8.89MM | $xx.xx | $607.01MM | Ayurmaya Capital Management, Foresite Capital | |
Price per Share
$xx.xx
Shares Outstanding
1,778,830
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ayurmaya Capital Management, Foresite Capital
|
||||||
01/06/2022 | Series B | $201MM | $xx.xx | $483.98MM | Matrix Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
40,200,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Matrix Capital Management
|
||||||
05/05/2021 | Series A | $30MM | $xx.xx | $185.07MM | Foresite Capital | |
Price per Share
$xx.xx
Shares Outstanding
7,500,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital
|
||||||
05/05/2021 | Series B-1 | $39.04MM | $xx.xx | $185.07MM | Foresite Capital | |
Price per Share
$xx.xx
Shares Outstanding
9,760,088
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital
|
||||||
01/29/2021 | Series Seed | $10.5MM | $xx.xx | $23.33MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
10,500,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|